Renal impairment refers to the condition in which the kidneys lose their ability to effectively filter waste and excess fluids from the blood. It affects millions of people worldwide, including 700 million individuals with chronic kidney disease (CKD) and those suffering from acute kidney injury (AKI) or kidney failure, such as dialysis and transplant patients. Driven by factors like diabetes and hypertension, renal impairment is a growing global health concern. Despite its high prevalence, there is a significant unmet clinical need for better therapies, as current treatments like dialysis and transplants fail to offer a cure or substantial improvements in quality of life. Advances in early detection, personalized medicine, and nephrology research are expected to drive future pipeline growth and enhance patient outcomes.
The Renal Impairment Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into renal impairment therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for renal impairment. The renal impairment report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The renal impairment pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with renal impairment treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to renal impairment.
Renal impairment refers to the decreased ability of the kidneys to filter waste and maintain fluid balance, leading to an accumulation of toxins in the body. It occurs due to conditions like diabetes, hypertension, or glomerulonephritis. The drug pipeline focuses on therapies targeting kidney function restoration, slowing progression, and alleviating symptoms associated with chronic kidney disease and acute kidney injury, including novel drug candidates and biologics in clinical trials.
Renal impairment treatment aims to manage underlying causes, reduce complications, and slow progression. Medications help to control blood pressure and improve kidney function. Dialysis is used for severe cases, while kidney transplantation offers a long-term solution for end-stage renal disease. Emerging therapies focus on regenerative approaches and reducing fibrosis to preserve kidney function.
In the United States, an estimated 35.5 million individuals suffer from kidney disease, with 808,000 living with kidney failure while in in India, 13% to 15% of the population is affected. In the United Kingdom, around 7.2 million people have chronic kidney disease, with 3.25 million in advanced stages requiring complex management.
This section of the report covers the analysis of renal impairment drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total renal impairment clinical trials.
The drug molecule categories covered under the renal impairment pipeline analysis include small molecules, monoclonal antibodies, peptides, RNA-based therapies, and immune modulators. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for renal impairment.
The EMR renal impairment drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Renal Impairment clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for renal impairment. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of renal impairment drug candidates.
The Phase 3 clinical study, sponsored by Daewoong Pharmaceutical Co. Ltd., aims to evaluate the efficacy and safety of DWP16001 in patients with type 2 diabetic nephropathy and moderate renal impairment (CKD stage 3). The study is set to begin on September 23, 2024, with an expected completion by January 31, 2027, and will involve 348 participants.
Sponsored by the Hellenic Society of Hematology, this Phase 2 study evaluates the efficacy and safety of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone, followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment. The study, expected to be completed by February 2025, will include 51 participants.
Merck Sharp & Dohme LLC is sponsoring this Phase 1 clinical study to assess the pharmacokinetics of Enlicitide in participants with severe renal impairment. The study will compare the drug's behavior in both impaired and healthy individuals. It is set to involve 24 participants, with an expected completion date of May 8, 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Renal Impairment Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for renal impairment. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within renal impairment pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share